Table 3.

Clinical assessments

	N	Median	IQR	Max	Min	Z value	p value
Walking speed (m/s)
Baseline ITT-PMS study	12	1.00	0.37	1.59	0.44
Endpoint in extension trial	13	0.65	0.67	1.56	0.10
Change	11	− 0.33	0.38	0.06	− 0.91	− 2.756	0.006
9HPT—Dominant hand
Baseline ITT-PMS study	15	25.00	20.40	56.10	17.00
Endpoint in extension trial	14	26.38	34.55	114.65	16.60
Change	14	0.25	6.95	71.44	− 6.00	0.471	0.638
9HPT—non-dominant hand
Baseline ITT-PMS study	15	27.40	12.45	58.50	21.35
Endpoint in extension trial	15	30.30	18.55	56.90	19.45
Change	15	2.30	8.04	30.50	17.65	0.568	0.570
FSMC
Cognitive Score
Baseline ITT-PMS study	15	32	12	42	12
Endpoint in extension trial	15	32	14	48	20
Change	15	1	11	13	− 12	0.220	0.826
Motor Score
Baseline ITT-PMS study	15	41	7	50	19
Endpoint in extension trial	15	36	10	48	29
Change	15	− 4	8	12	− 15	− 1.592	0.111
Total Score
Baseline ITT-PMS study	15	74	15	87	31
Endpoint in extension trial	15	67	23	95	54
Change	15	− 2	18	25	− 27	− 1.194	0.232
SDMT
Baseline ITT-PMS study	15	48	15	65	22
Endpoint in extension trial	15	49	19	68	23
Change	15	1	6	13	− 6	2.404	0.016

Results from clinical assessments of the 15 participants that completed the full 3-year ITT-PMS + ITT-PMS extension studies